Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada

References

• GoffDCHillMFreudenreichOStrategies for improving treatment adherence in schizophrenia and schizoaffective disorderJ Clin Psychiatry201071Suppl 2202621190649
   PubMed Web of Science ®Google Scholar
• LambertTOlivaresJMPeuskensJEffectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumAnn Gen Psychiat20111010
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• LawMRSoumeraiSBRoss-DegnanDAdamsASA longitudinal study of medication nonadherence and hospitalization risk in schizophreniaJ Clin Psychiatry2008691475318312037
   PubMed Web of Science ®Google Scholar
• ChuePSHeegBBuskensEvan HoutBAModelling the impact of compliance on the costs and effects of long-acting risperidone in CanadaPharmacoeconomics200523Suppl 1627416416762
   PubMed Web of Science ®Google Scholar
• KnappMKingDPugnerKLapuertaPNon-adherence to antipsychotic medication regimens: associations with resource use and costsBr J Psychiatry200418450951615172945
   PubMed Web of Science ®Google Scholar
• GoereeRFarahatiFBurkeNThe economic burden of schizophrenia in Canada in 2004Curr Med Res Opin200521122017202816368053
   PubMed Web of Science ®Google Scholar
• AdamsCEFentonMKQuraishiSDavidASSystematic meta-review of depot antipsychotic drugs for people with schizophreniaBr J Psychiatry200117929029911581108
   PubMed Web of Science ®Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry2009195S63S67
   Web of Science ®Google Scholar
• HaddadPMTaylorMNiazOSFirst-generation antipsychotic long-acting injections v oral antipsychotics in schizophrenia: systematic review of randomized controlled trials and observational studiesBr J Psychiatry Suppl200952S20S2819880913
   PubMedGoogle Scholar
• TaylorDPsychopharmacology and adverse effects of antipsychotic long-acting injections: a reviewBr J Psychiatry Suppl200952S13S1919880912
   PubMedGoogle Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry2004161341442514992963
   PubMed Web of Science ®Google Scholar
• LeuchtSKisslingWDavisJMSecond-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychol Med200939101591160219335931
   PubMed Web of Science ®Google Scholar
• ValensteinMBlowFCCopelandLAPoor antipsychotic adherence among patients with schizophrenia: medication and patient factorsSchizophr Bull200430225526415279044
   PubMed Web of Science ®Google Scholar
• KaneJMEerdekensMLindenmayerJPKeithSTLesemMKarcherKLong-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychoticAm J Psychiatry200316061125113212777271
   PubMed Web of Science ®Google Scholar
• FleischhackerWWEerdekensMKarcherKTreatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychoticJ Clin Psychiatry200364101250125714658976
   PubMed Web of Science ®Google Scholar
• ChuePEerdekensMAugustynsIComparative efficacy and safety of long-acting risperidone and risperidone oral tabletsEur Neuropsychopharmacol200515111111715572280
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomized long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• HaddadPMTiihonenJHaukkaJTaylorMPatelMXKorhonenPThe place of observational studies in assessing the effectiveness of depot antipsychoticsSchizophr Res20111311–326026121665440
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceSchizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary CareLeicester/LondonBritish Psychological Society and Royal College of Psychiatrists2010 Available from: http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdfAccessed December 5, 2013
   Google Scholar
• OlivaresJMRodriguez-MoralesADielsJLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847
   PubMed Web of Science ®Google Scholar
• PeuskensJOlivaresJMPecenakJTreatment retention with risperidone long-acting injection: 24-month results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countriesCurr Med Res Opin201026350150920014981
   PubMed Web of Science ®Google Scholar
• ApiquianRCórdobaRLouzãMClinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin AmericaNeuropsychiatr Dis Treat201071192621326651
   PubMed Web of Science ®Google Scholar
• OlivaresJMPeuskensJPecenakJResselerSJacobsAAkhrasKSClinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registryCurr Med Res Opin20092592197220619604073
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MartinezABurónJAAlonso-EscolanoDRodriguez-MoralesACost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in SpainAppl Health Econ Health Policy200861415318774869
   PubMedGoogle Scholar
• GuyWClinical global impressionRushAJHandbook of Psychiatric MeasuresWashingtonAmerican Psychiatric Association2000100102
   Google Scholar
• EndicottJSpitzerJFleissJCohenJThe global assessment scale. A procedure for measuring overall severity of psychiatric disturbanceArch Gen Psychiatry1976336766771938196
   PubMed Web of Science ®Google Scholar
• MorosiniPLMaglianoLBranbillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioningActa Psychiatr Scand2000101432332910782554
   PubMed Web of Science ®Google Scholar
• ErikssonLAlmqvistAMehnertALong-acting risperidone significantly reduces the need for institutional psychiatric carePoster presented at: 42nd Annual Meeting of the American College of NeuropsychopharmacologyDecember 7–11, 2003San Juan, Puerto Rico
   Google Scholar
• NasrallahHMorosiniPGagnonDDReliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophreniaPsychiat Res20081612213224
   PubMed Web of Science ®Google Scholar
• BeauclairLChuePMcCormickJCamachoFLamALuongDImpact of risperidone long-acting injectable on hospitalization and medication use in Canadian patients with schizophreniaJ Med Econ2007104427442
   Google Scholar
• PatrickDLBurnsTMorosiniPGagnonDDRothmanMAdriaenssenIMeasuring social functioning with the Personal and Social Performance Scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tabletsClin Ther201032227529220206786
   PubMed Web of Science ®Google Scholar
• NasrallahHALasserRImproving patient outcomes in schizophrenia: achieving remissionJ Psychopharmacol200620Suppl 6576117046987
   PubMedGoogle Scholar
• Health CanadaSummary basis of decision: Invega, Sustenna2010 Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2010_invega_sustenna_127385-eng.pdfAccessed August 1, 2013
   Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201135121822621092748
   PubMed Web of Science ®Google Scholar